Literature DB >> 3379401

Presence of kynurenic acid in the mammalian brain.

F Moroni1, P Russi, G Lombardi, M Beni, V Carlà.   

Abstract

Kynurenic acid, a tryptophan metabolite able to antagonize the actions of the excitatory amino acids, has been identified and measured for the first time in the brain of mice, rats, guinea pigs, and humans by using an HPLC method. Its content was 5.8 +/- 0.9 in mouse brain, 17.8 +/- 2.0 in rat brain, 16.2 +/- 1.5 in guinea pig brain, 26.8 +/- 2.9 in rabbit brain, and 150 +/- 30 in human cortex (pmol/g wet wt. mean +/- SE). The regional distribution of this molecule was uneven. In rats, guinea pigs, and rabbits, the brainstem was the area richest in this compound. Tryptophan administration (100-300 mg/kg, i.p.) to rats resulted in a significant increase of the brain content of kynurenic acid. Similarly, 1 h after probenecid administration (200 mg/kg, i.p.), the brain content of kynurenate increased by fourfold, thus suggesting that its turnover rate is relatively fast.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3379401     DOI: 10.1111/j.1471-4159.1988.tb04852.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  53 in total

1.  Tryptophan therapy for non-ketotic hyperglycinaemia.

Authors:  F Inoue; S Matsuo; H Yoshioka; Y Takeuchi; H Yamanaka; N Kodo; A Kinugasa; T Sawada
Journal:  J Inherit Metab Dis       Date:  1992       Impact factor: 4.982

2.  Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia.

Authors:  Klas R Linderholm; Elisabeth Skogh; Sara K Olsson; Marja-Liisa Dahl; Maria Holtze; Göran Engberg; Martin Samuelsson; Sophie Erhardt
Journal:  Schizophr Bull       Date:  2010-08-20       Impact factor: 9.306

3.  Kynurenic acid inhibits the release of the neurotrophic fibroblast growth factor (FGF)-1 and enhances proliferation of glia cells, in vitro.

Authors:  Claudia Di Serio; Andrea Cozzi; Ilaria Angeli; Laura Doria; Isabella Micucci; Silvia Pellerito; Patrizia Mirone; Giulio Masotti; Flavio Moroni; Francesca Tarantini
Journal:  Cell Mol Neurobiol       Date:  2005-09       Impact factor: 5.046

Review 4.  Kynurenic acid as an antagonist of α7 nicotinic acetylcholine receptors in the brain: facts and challenges.

Authors:  Edson X Albuquerque; Robert Schwarcz
Journal:  Biochem Pharmacol       Date:  2012-12-25       Impact factor: 5.858

5.  Kynurenine in combination with probenecid mitigates the stimulation-induced increase of c-fos immunoreactivity of the rat caudal trigeminal nucleus in an experimental migraine model.

Authors:  E Knyihár-Csillik; J Toldi; A Mihály; B Krisztin-Péva; Z Chadaide; H Németh; R Fenyo; L Vécsei
Journal:  J Neural Transm (Vienna)       Date:  2006-08-10       Impact factor: 3.575

6.  Modulation of the function of presynaptic alpha7 and non-alpha7 nicotinic receptors by the tryptophan metabolites, 5-hydroxyindole and kynurenate in mouse brain.

Authors:  M Grilli; L Raiteri; L Patti; M Parodi; F Robino; M Raiteri; M Marchi
Journal:  Br J Pharmacol       Date:  2006-10-03       Impact factor: 8.739

7.  Kynurenic acid leads, dopamine follows: a new case of volume transmission in the brain?

Authors:  H-Q Wu; A Rassoulpour; R Schwarcz
Journal:  J Neural Transm (Vienna)       Date:  2006-08-24       Impact factor: 3.575

8.  Preferential Disruption of Prefrontal GABAergic Function by Nanomolar Concentrations of the α7nACh Negative Modulator Kynurenic Acid.

Authors:  Eden Flores-Barrera; Daniel R Thomases; Daryn K Cass; Ajay Bhandari; Robert Schwarcz; John P Bruno; Kuei Y Tseng
Journal:  J Neurosci       Date:  2017-07-20       Impact factor: 6.167

Review 9.  Pharmacological manipulation of kynurenic acid: potential in the treatment of psychiatric disorders.

Authors:  Sophie Erhardt; Sara K Olsson; Göran Engberg
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

10.  The astrocyte-derived alpha7 nicotinic receptor antagonist kynurenic acid controls extracellular glutamate levels in the prefrontal cortex.

Authors:  Hui-Qiu Wu; Edna F R Pereira; John P Bruno; Roberto Pellicciari; Edson X Albuquerque; Robert Schwarcz
Journal:  J Mol Neurosci       Date:  2009-08-19       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.